1. Home
  2. DCTH

DCTH

Delcath Systems Inc.

Logo Delcath Systems Inc.

Health Care

Medical/Dental Instruments

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Founded: 1988 Country:
United States
United States
Employees: N/A City: QUEENSBURY
Market Cap: 123.9M IPO Year: N/A
Target Price: $18.50 AVG Volume (30 days): 203.8K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.94 EPS Growth: N/A
52 Week Low/High: $2.25 - $7.99 Next Earning Date: 05-10-2024
Revenue: $2,065,000 Revenue Growth: -24.05%
Revenue Growth (this year): 1179.85% Revenue Growth (next year): 171.04%

Share on Social Networks: